transcription, blood fl ow, neuroinfl ammation, and other parameters (1) (2) (3) . These PUFAs are concentrated in the stereospecifi cally numbered-2 position of synaptic membrane phospholipids, from which they can be hydrolyzed by phospholipases A 2 enzymes (PLA 2 , EC 3.1.1.4) ( 3-5 ).
Four major PLA 2 subclasses are described in mammalian brain based on in vitro studies: Ca 2+ -dependent cytosolic cPLA 2 type IV [cPLA 2 ␣ (type IVA) and ␤ are Ca 2+ -dependent, cPLA 2 ␥ is not], Ca 2+ -dependent secretory sPLA 2 , Ca 2+ -independent iPLA 2 ( ␤ and ␥ ), and Ca 2+ -independent plasmalogen PLA 2 ( 6, 7 ) . cPLA 2 ( ␣ and ␤ ) requires a low concentration of Ca 2+ for its translocation to the membrane and activation (0.3-1 M) and is selective for AA during acute stimulation of cells by diverse agents in vitro ( 8, 9 ) . iPLA 2 does not require Ca 2+ for activation (10) (11) (12) and is selective for DHA in isolated glial cells and in the test tube ( 13 ) . Plasmalogen PLA 2 releases DHA from plasmalogen ethanolamine ( 7, 14 ) . sPLA 2 requires millimolar Ca 2+ concentrations for activation and releases AA and DHA in vitro ( 6, 7 ) . cPLA 2 and iPLA 2 have been identifi ed at postsynaptic sites and glia in the vertebrate brain, sPLA 2 at presynaptic sites, and plasmalogen PLA 2 in neurons and glia ( 7, (15) (16) (17) . Despite their different brain distributions and varying Ca 2+ dependencies shown by in vitro studies, little information is available about the in vivo roles of the different PLA 2 enzymes to brain signaling involving AA and DHA. We therefore thought it of interest to examine and compare how in vivo signaling involving the two PUFAs depends on entry of extracellular Ca 2+ in cells. In this regard, binding of glutamate or N-methyl-Daspartic acid (NMDA) to ionotropic NMDA receptors that are highly expressed in brain ( 18 ) 
Surgical procedures and tracer infusion
In the morning of an experiment, a rat was anesthetized with 2-3% halothane in O 2 . Polyethylene catheters were inserted into the right femoral artery and vein, as described ( 26 ) . The rat was allowed to recover from anesthesia for 3 h in a sound-dampened, temperature-controlled box with its hindquarters loosely wrapped and taped to a wooden block. Arterial blood pressure and heart rate were measured with a blood pressure recorder (CyQ 103/302; Cybersense, Inc., Nicholasville, KY). Arterial blood pH, partial pressure of oxygen (pO 2 ), and partial pressure of carbon dioxide (pCO 2 ) were measured with a blood gas analyzer (Model 248, Bayer Health Care, Norwood, MA).
Ten min after i.p. saline or i.p. NMDA (25 mg/kg), or 30 min after MK-801 (0.3 mg/kg i.p.), [1- 14 C]DHA (170 µCi/kg) was infused into the femoral vein for 5 min at a rate of 400 µl/min using an infusion pump (Harvard Apparatus Model 22, Natick, MA) ( 26 ) . For studies with both drugs, MK-801 was administered 30 min prior to NMDA, which was given 10 min before the radioisotope. For the AA study, saline or NMDA (25 mg/kg) was injected 10 min before [1- 14 C]AA (170 µCi/kg) infusion. Twenty min after beginning tracer infusion in either case, the rat was euthanized with Nembutal® (80 mg/kg, i.v.). The brain was removed within 30 s, frozen in 2-methylbutane maintained at Ϫ 40°C with dry ice, and stored at Ϫ 80°C.
Chemical analysis
Thirteen arterial blood samples, collected before, during, and after [1- 14 C]AA or [1-14 C]DHA infusion, were centrifuged immediately (30 s at 18,000 g ) to determine unesterifi ed plasma DHA or AA radioactivity. Total lipids were extracted from 30 µl plasma with 3 ml chloroform:methanol (2:1, v/v) and 1.5 ml KCl (0.1 M) ( 32 ). Radioactivity was determined in 100 µl of the organic phase by liquid scintillation counting. As reported, after a 5 min [1- 14 C] AA or [1- 14 C]DHA infusion, >97% of plasma radioactivity was the infused radiolabeled PUFA ( 33, 34 ) . C]fatty acid infusion. Integrated plasma radioactivity (input function in denominator) was determined in each experiment by trapezoidal integration and used to calculate k* for each experiment.
Quantitative autoradiography

Statistical analyses
Physiological parameters were analyzed by paired t -tests in the same animal before and after drug injection (GraphPad Prism Software, San Diego, CA). Statistical signifi cance of drug on arterial plasma radioactivity and on k* for each brain region was determined by one-way ANOVA (ANOVA) with Dunnett's post-test cPLA 2 to release AA from membrane phospholipid (19) (20) (21) . Increments in intracellular Ca 2+ following NMDA are р 1 M ( 22, 23 ). Using our imaging method involving the intravenous infusion of [1- 14 C]AA ( 24, 25 ) , we reported that administration of a subconvulsive dose of NMDA (25 mg/kg i.p.) to unanesthetized rats increased AA signaling, measured as increased AA incorporation coeffi cients k*, in wide areas of brain (26) (27) (28) . The increases could be blocked by pretreatment with the NMDA receptor antagonist MK-801, which by itself reduced baseline values of k* by 16-49% ( 26 ) .
In the present study, we employed our in vivo imaging method to determine the dependence of in vivo brain DHA signaling on extracellular Ca 2+ , compared to AA signaling. We hypothesized that the DHA signal would not be altered following NMDA, to the extent that it is mediated by iPLA 2 , plasmalogen PLA 2 , or another Ca 2+ -independent enzyme (see above). We administered (i.p.) isotonic saline, a subconvulsive dose of NMDA (25 mg/kg), MK-801, or MK-801 followed by NMDA, to unanesthetized male adult rats. Radiolabeled DHA (or AA as a control) was infused intravenously for 5 min, and brain incorporation coeffi cients k* were imaged using quantitative autoradiography at 20 min. We confi rmed that NMDA widely increased AA incorporation coeffi cients k* in brain, whereas it had no signifi cant effect on DHA incorporation coefficients in any of 81 measured brain regions. Thus, extracellular-derived Ca 2+ and cPLA 2 are not involved in brain DHA signaling in vivo.
MATERIALS AND METHODS
Animals
Experiments were conducted following the "Guide for the Care and Use of Laboratory Animals" (National Institutes of Health Publication No. 86-23) and were approved by the Animal Care and Use Committee of Eunice Kennedy Shriver National Institute of Child Health and Human Development. Threemonth-old male Fischer F344 rats (Taconic Farms, Rockville, MD) were acclimated for 1 week in an animal facility having regulated temperature, humidity, and a light-dark cycle. The rats had ad libitum access to water and food (Rodent NIH-31 auto 18-4 diet, Zeigler Bros, Gardners, PA). The diet contained (as percent of total fatty acids) 20.0% saturated, 22.5% monounsaturated, 47.9% linoleic, 5.1% ␣ -linolenic, 0.2% AA, 2.0% eicosapentaenoic, and 2.3% DHA acids ( 29 ) .
Drugs
NMDA and MK-801 ((5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate) were purchased from Sigma-Aldrich (Saint Louis, MO) and 0.9% NaCl (saline USP) was purchased from Hospira (Lake Forest, IL). 
drug effects. Data are reported as mean ± SD, with statistical signifi cance set at P р 0.05.
RESULTS
Physiology and arterial plasma radioactivity
For the DHA infusion study, NMDA (25 mg/kg, i.p.) compared with saline signifi cantly decreased heart rate by 11% (387 ± 46 versus 442 ± 25 beats/min, P < 0.05) but did not have a signifi cant effect on arterial blood pressure, whereas MK-801 alone or before NMDA increased systolic arterial blood pressure by 9-13% in the unanesthetized rats ( P < 0.05; n = 7-8). Arterial blood pressure (mmHg) was as follows: before MK-801 (169 ± 10); after MK-801 (184 ± 9); before MK-801 and NMDA (176 ± 10); after MK-801 and NMDA (199 ± 22). Such changes, reported previously, have been ascribed to a centrally mediated increase in sympathetic nerve activity by MK-801 ( 26 ) . MK-801 given before NMDA abolished NMDA's signifi cant effect on heart rate and decreased plasma pH (data not shown).
A one-way ANOVA with Dunnett's test showed that MK-801 signifi cantly ( P < 0.01) increased mean integrated radioactivity by 42% in the plasma organic fraction, the input function for determining k* in equation 1 during [1- For the reference AA infusion study, NMDA signifi cantly decreased heart rate by 16% (data not shown). Unpaired t -tests showed that NMDA signifi cantly increased integrated plasma radioactivity during [1- 14 C]AA infusion by 21% ( P = 0.04) [NMDA (114,173 ± 20,236) versus saline (94,118 ± 15,356) nCi/s/ml].
Regional brain DHA and AA incorporation coeffi cients, k*
As shown in Table 1 and Fig. 1 , NMDA compared with saline did not increase k* for DHA signifi cantly in any of the 81 regions examined. Also, MK-801 given alone or 30 min prior NMDA had no effect on k* for DHA in any region (data not shown). In contrast, NMDA compared with saline significantly increased k* for AA by 20-86% in 54 of 81 regions. Affected regions included prefrontal cortex (38-46%), frontal cortex (23-30%), piriform cortex (32%), motor cortex (40-58%), somatosensory cortex (32-41%), auditory cortex (25-39%), hippocampus (40-86%), nucleus accumbens (26%), caudate putamen (39-48%), septal nuclei (44-70%), some regions of the thalamus (20-38%), hypothalamus (24-72%), two white matter regions (58-77%), and two nonblood brain barrier regions (51-69%).
DISCUSSION
An acutely administered subconvulsive dose of NMDA (25 mg/kg i.p.) in unanesthetized rats, compared with i.p. saline control, failed to induce a signifi cant change in the brain DHA incorporation coeffi cient k* in any of 81 regions imaged using quantitative autoradiography. MK-801 also had no effect on baseline k* for DHA. In contrast, we confi rmed the report that this dose of NMDA signifi cantly increased k* for AA in wide areas of the brain (26) (27) (28) .
The baseline values of k* for DHA and AA in this study agree with published data (26) (27) (28) 30 ) . k* for each PUFA largely refl ects its metabolic loss following its release from membrane phospholipid, as DHA and AA cannot be synthesized de novo in vertebrate tissue and only negligible amounts (< 1%) can be elongated in brain from their circulating precursors ␣ -linolenic (18:3n-3) and linoleic acid (18:2n-6), respectively. Loss is replaced entirely by unesterifi ed PUFA from plasma ( 2, 29, 36 ) .
The statistically signifi cant increments in k* for AA following NMDA are thought to arise from entry of extracellular Ca 2+ into the cell through ionic NMDA receptors to activate cPLA 2 and selectively hydrolyze AA from synaptic membrane phospholipid ( 4, 6, 8, 9, 20, 21 . In contrast, the absence of DHA responses to NMDA indicates that the DHA signal is independent of extracellular-derived Ca 2+ and cPLA 2 , and thus likely mediated by a PLA 2 whose activation is independent of entry of increments in intracellular Ca 2+ of about 1 M. As discussed above, potential Ca 2+ -independent candidates are iPLA 2 ( ␤ and ␥ ) and plasmalogen PLA 2 , and cPLA 2 ␥ ( 6, 7, 10-13, 37, 38 ). sPLA 2 is an unlikely candidate because of its presynaptic location and its mM requirement for Ca 2+ ( 6, 39 ) . Supporting a role for iPLA 2 ␤ in DHA signaling in vivo, k* for DHA at rest or in response to stimulation of G-protein-coupled cholinergic muscarinic M 1,3,5 receptors by arecoline is decreased in unanesthetized heterozygous and homozygous iPLA 2 ␤ (VIA)-defi cient mice ( 40 ) . Additionally, in rats whose diets are defi cient in n-3 PUFAs, mRNA, protein, and activity levels of iPLA 2 ␤ are reduced in relation to reduced DHA turnover in brain phospholipid ( 41, 42 ) .
The absence of signifi cant reductions in k* for DHA following MK-801, in contrast to 16-49% reductions reported for k* for AA following MK-801(26), further indicates that endogenous glutamate is not involved in baseline DHA release. In agreement, exposure of eosinophilic leukemia cells or platelets to a Ca 2+ -ionophore did not release DHA while releasing AA through cPLA 2 activation ( 9 ), and chronic NMDA administration to rats increased cPLA 2 -IVA but not iPLA 2 -VI expression in brain ( 43 ) . Under some in vitro conditions, acute NMDA receptor activation may release Ca 2+ from intracellular stores by Ca 2+ -induced Ca 2+ release (CICR) ( 44, 45 ) , which may indirectly stimulate iPLA 2 (46) (47) (48) . However, our in vivo data do not support this signaling pathway with the dose of NMDA administered. Our observations may be relevant to excitotoxicity, which involves high brain glutamate concentrations. In rodent models, excitotoxicity is associated with increased brain concentrations of AA and of its proinfl ammatory metabolites and with increased cPLA 2 -IVA expression, without a signifi cant change in DHA concentration or iPLA 2 -VI expression ( 43, 49, 50 ) . High concentrations of AA and its metabolites can be neurotoxic ( 51 ), whereas DHA and its metabolites are considered neuroprotective ( 1 ). Thus, increased release of AA but not of DHA due to excessive NMDA receptor activation by glutamate may interfere with brain function and structure ( 2, 52 ) .
In summary, stimulating brain NMDA receptors in unanesthetized rats by a subconvulsive dose of NMDA does not produce a signifi cant DHA signal, but it produces a robust AA signal. As such stimulation allows extracellular Ca 2+ into the cell, these in vivo results are consistent with in vitro evidence that AA is preferentially hydrolyzed from phospholipid by Ca 2+ -dependent cPLA 2 and that the in vivo AA signal following NMDA is a surrogate marker of Ca 2+ entry into cells. The absence of a DHA signal in rat brain following NMDA is consistent with in vitro evidence that DHA hydrolysis can be mediated by iPLA 2 , plasmalogen PLA 2 , and cPLA 2 ␥ , none of which requires Ca 2+ . Several human diseases, including Alzheimer disease and bipolar disorder, show upregulated cPLA 2 -IVA but not iPLA 2 ␤ expression, with high glutamatergic function and other evidence of excitotoxicity (53) (54) (55) (56) . Excess release of AA compared with DHA from membrane phospholipid would be expected to disturb the normally balanced interactions between the two PUFAs ( 52 ) and disrupt brain function in these diseases.
